U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.				
NPTO	Confirmation Number	6421		
ATION DISCLOSURE ENT BY APPLICANT	Application Number	10/742,346		
	Filing Date	December 19, 2003		
	First Named Inventor	Falotico		
	Group Art Unit	1615		
use as many sheets as necessary)	Examiner Name	C. Azpuru		
Sheet 1 of 2	Attorney Docket Number	CRD5062USNP		

U.S. PATENT DOCUMENTS

PTO/SB/08b (04-07)

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
	_	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	2		
Examiner's	, (,,,,,		T^2		
Initials*	No. ¹	e manuscript and a second process of a second			
/CH/		CAMPBELL, J., et al. "Cell Biology of Smooth Muscle in Culture: Implications for			
, 511/		Atherogenesis", Inter. Angio, 6, 1987, pp. 73-79			
		COLBURN, M., et al. "Dose Responsive Suppression of Myointimal Hyperplasia by			
		Dexamethasone", journal of Vascular Surgery, 15:510-518 (1992)			
		FRANKLIN, S., et al. "Pharmacologic Prevention of Restenosis After Coronary			
		Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease,			
		Vol., 4 No. 3, pp. 232-242 (1993)			
		MAK, K., et al. "Clinical Trials to Prevent Restenosis after Percutaneous Coronary			
		Revascularization", Ann. NY Academy of Science, 811 pp. 255-284 (1997)			
		POMPA, J., et al. Clinical Trials of Restenosis After Coronary Angioplasty",			
.		Circulation 84(3) p. 1426-1436 (1991)			
-	YOKOI, H., et al. "Effectiveness of an Antioxidant in Preventing Restenosis After				
		Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty			
- $$		Restenosis Trial", JACC, 3(4): p. 855-862 (1997)			
		ποσιοποσίο ττιαι , στοσο, σ(+). μ. σσο-σσε (1σστ)			

Examiner	/Caralvnne Helm/	Date	01/06/2009
Signature	/ Cararynne nerm/	Considered	01/00/2003

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450tance in completing the form, call 1-800-PTO-9199 and select option 2.